Headquartered in Irving, TX·Fiscal year ends March·NYSE: MCK·mckesson.com
About McKesson
McKesson Corporation is a diversified healthcare services company that works with biopharma companies, care providers, pharmacies, manufacturers and governments. It provides pharmaceutical distribution, specialty and oncology services, prescription technology and medical-surgical supplies. It reports four segments:
- **North American Pharmaceutical:** Drug distribution, including specialty products, to retail pharmacies, health systems and strategic accounts such as CVS Health, with a partnership extended through June 2032.
- **Oncology & Multispecialty:** Specialty distribution and provider solutions, including community oncology and the PRISM Vision Group ophthalmology network of more than 350 providers. The recently acquired Precision Medicine Group adds clinical research and biopharma commercialization services.
- **Prescription Technology Solutions:** Access solutions, third-party logistics and hub dispensing services for biopharma manufacturers.
- **Medical-Surgical Solutions:** Medical-surgical products for extended and ambulatory care. McKesson intends to separate this business into an independent company, and Apollo Funds holds an approximately 13% minority stake.
McKesson has also agreed to acquire an approximately 49% minority interest in home and community infusion provider Option Care Health. Updated
McKesson set another record high at $1,105.15, topping the mark it just made on Nov. 13. Rival Cardinal Health rose 0.97% while customer CVS Health slipped 0.82%.
Before the movelast 24 hours
Jim Cramer
We just get me into McKesson. Please. Can I just have some Amgen?
New 52-week high$1,069.02+3.8% vs prior high · 2026-10-20
McKesson cleared $1,069.02, a record 52-week high that sits 3.78% above its October 20 peak, hours after the company filed its fiscal Q2 2027 earnings.
Management lifted full-year adjusted EPS guidance to $45.60 to $46.40, a fifth straight quarter of beating consensus. Specialty distribution carried it: Oncology and Multispecialty growth more than covered a profit drop in the Medical-Surgical unit being spun off.
Earnings · 2027 Q2Brian S. TylerChief Executive Officer, McKesson
“McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise.
CEO Brian Tyler's fiscal Q2 framing leans on core distribution strength, and the $124.6 billion drug wholesaler slipped slightly after he said it. With Cencora already raising its 2026 outlook on specialty momentum, the segment detail behind that "disciplined execution" is what decides whether McKesson keeps pace.
Earnings · 2027 Q2Brian S. TylerChief Executive Officer, McKesson
“We continue to invest strategically to advance healthcare outcomes and create long-term value. We further strengthened our portfolio through transactions that will expand our capabilities and deepen our presence in key growth areas, while maintaining our commitment to financial discipline.
Tyler is telling fiscal Q2 investors that the $124.6 billion distributor is leaning on acquisitions to push deeper into oncology and specialty care beyond basic drug distribution. The dealmaking message landed softly, with shares slightly lower since the remarks. Watch how much growth guidance rides on integrating those purchases.
Earnings · 2027 Q2Brian S. TylerChief Executive Officer, McKesson
“We are confident in our ability to leverage differentiated solutions and create value for customers, partners, patients, and shareholders.
Tyler's confidence line came on McKesson's fiscal 2027 second quarter call, and the $124.6 billion distributor slipped 0.85% since. Investors want specifics on oncology and biopharma services growth, so the follow-through in guidance detail is what matters here.
A 4.57% jump to $1,065.70 adds roughly $5 billion to this $124 billion distributor, and it comes after Cencora, a competitor, filed Q4 earnings. McKesson has followed 3 of the last 4 Cencora reports with an average 4.4% move.
New 52-week high$998.64+0.5% vs prior high · 2026-03-03
McKesson just set a fresh 52-week high at $998.64, knocking on $1,000 for the first time. The distributor has clawed back a summer drawdown that took it under $740.
Accenture opened 22% higher, a move you almost never see from a mega-cap IT services name, while Corteva dropped 82% to $13.96 at the other end of the board. Synopsys, McKesson and IBM round out a gainers list that is all up at least 5.9%.
One Number: $7.2 Million in Revenue Per Employee NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) now brings in about $7.2 million in revenue for each person on its payroll. That figure comes from…
All the major Wall Street firms we cover here at 24/7 Wall St. have a list of the top stock picks for their institutional and retail clients to invest in. Typically, these…
William Blair launched coverage of Cardinal Health (NYSE:CAH | CAH Price Prediction) with an Outperform rating today, framing the pharma distributor as a durable franchise with specialty-led upside. The firm simultaneously initiated…
Somehow, members of Congress have turned relatively modest salaries into impressive investment portfolios while the rest of us grind it out in the market. For years, questions have swirled around lawmakers buying…
UnitedHealth Group (NYSE:UNH | UNH Price Prediction) has faced severe headwinds in 2025, with its stock plummeting over 50% from its April high. This decline was driven by a rare first-quarter earnings…
Investing in dividend growth stocks is a smart, reliable way to build passive income that lasts a lifetime, and it’s worth considering if you’re eyeing financial freedom. These are companies that have…
While dividend stock investing is one of the best strategies an investor can pursue to create phenomenal wealth, chasing yield can undermine the entire effort. Buying dividend stocks simply because the yields…
These five top companies are Wall Street favorites and are expected to raise their dividends this week, showing that they are doing well and have the earnings and cash flow strength to…
Monday's top analyst upgrades and downgrades included BlackBerry, Cardinal Health, Comstock Resources, Howmet Aerospace, JD.com, Pacific Biosciences of California, Restaurant Brands, Tenaris and Wendy’s.
Monday's top analyst upgrades and downgrades included Bill.com, Cigna, ConocoPhillips, Estee Lauder, Fortinet, Microchip Technology, Pfizer, Skyworks Solutions, Snap, Snowflake, VICI Properties and Wipro.
Monday's top analyst upgrades and downgrades included Airbnb, AT&T, Duke Energy, Etsy, FirstEnergy, Gap, IBM, KeyCorp, Kohl's, Las Vegas Sands, Nvidia, Starbucks, Trade Desk and Visa.
In a move that investors looking for more defensive ideas should applaud, the analysts at Goldman Sachs have added Bristol-Myers Squibb to the Americas Conviction List. Plus, here are four additional health…
McKesson Corporation is a diversified healthcare services company that works with biopharma companies, care providers, pharmacies, manufacturers and governments. It provides pharmaceutical distribution, specialty and oncology services, prescription technology and medical-surgical supplies.
What is the MCK stock price target?
24/7 Wall St.'s 12-month price target for MCK is $1,275.03, rated Buy. The Wall Street consensus target is $1,144.29. MCK price prediction →